Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A GHRH analog studied for sustained stimulation of the GH/IGF-1 axis; frequently paired with a GHRP in research protocols.
Evidence at a glance: Includes human-trial data
The cited record for this compound includes human-trial data. Each claim below still states its study type and population, so the scope of that evidence stays explicit.
Molecular identity
- Molecular formula
- C165H269N47O46
- Molecular weight
- 3647.2 g/mol
- CAS number
- 863288-34-0
- Amino acids
- 30
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 99.1%
Researched mechanism
GHRH receptor agonism; the DAC variant extends half-life via albumin binding.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Sustained GH/IGF-1 elevation characterized in early human studies.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Ipamorelin | Mechanism | Often co-studied: CJC-1295 (GHRH) + ipamorelin (GHRP). |
| Sermorelin | Half-life | CJC-1295 is longer-acting than sermorelin. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 3 weeks |
Common questions
Why is it paired with ipamorelin?+
Published protocols combine a GHRH analog with a GHRP; see the comparison and cited literature.
